Xeris Biopharma Holdings, Inc.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. carries a market capitalization of 1.20B, placing it among publicly traded companies globally. Its enterprise value stands at 1.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xeris Biopharma Holdings, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. has 173.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.96, and the price-to-book ratio stands at -140.66.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. trades at an EV/EBITDA multiple of 31.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 42.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.35B versus a market cap of 1.20B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,973.52, indicating conservative leverage, while an interest coverage ratio of 1.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4.60, reflecting losses generated across the asset base. The company generates approximately 691,201.59 in revenue per employee across its workforce of 424.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.61 indicates how many times Xeris Biopharma Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Xeris Biopharma Holdings, Inc.'s stock has gained approximately 23.97% over the past 52 weeks. The 50-day moving average sits at 7.96, while the 200-day moving average is 6.43.

Over the twelve months ended June 30, 2026, Xeris Biopharma Holdings, Inc. generated 293.59M in revenue and converted that into -15.02M in net income, yielding earnings per share of -0.08. EBITDA reached 43.24M, while operating income came in at 32.03M.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. holds 106.57M in cash and equivalents against 253.35M in total debt, resulting in a net debt position of 114.53M. Total book value stands at -8.52M, with working capital of 74.57M providing operational flexibility.

Xeris Biopharma Holdings, Inc. produced 49.55M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Xeris Biopharma Holdings, Inc. posted a gross margin of 86.58, reflecting its pricing power and cost economics. The operating margin of 10.91 and net profit margin of -5.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.05, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.49, meaning Xeris Biopharma Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Xeris Biopharma Holdings, Inc. has an Altman Z-Score of 0.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.